Abstract
Clinically significant hemorrhage, especially intracranial hemorrhage, is a major cause of morbidity and mortality in extremely preterm infants and is a rare event in otherwise healthy term infants. Infusions of FFP in newborn infants is effective in reducing blood loss associated with extracorporeal membrane oxygenation or cardiopulmonary bypass and to treat active bleeding due to disseminated intravascular coagulation, liver failure or vitamin K deficiency. However, routine use of fresh frozen plasma (FFP) in sick preterm infants for volume expansion, to treat coagulopathy in the absence of bleeding, or for partial exchange transfusion does not decrease mortality or morbidity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
